Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Switzerland aims to legalize medical marijuana

Published 2019-06-26, 05:41 a/m
© Reuters.  Switzerland aims to legalize medical marijuana
NOVN
-
TLRY
-

* Switzerland aims to legalize medical marijuana

* Plan is separate from recreational pot project

* Other European countries also adopting medical cannabis

By John Miller

ZURICH, June 26 (Reuters) - The Swiss government aims to make it easier for patients to get medical marijuana, proposing on Wednesday to allow prescriptions for cannabis to treat people suffering from cancer or other serious conditions.

The proposal, separate from a Swiss government push to allow some cities to experiment with recreational marijuana, would replace the current system, in which those seeking medical cannabis must apply for an exception from the Federal Health Office to get what is otherwise an illegal drug.

Marijuana is sometimes used to help cancer patients manage chronic pain, to help boost their appetites, and to reduce spasticity associated with multiple sclerosis.

"The proposal makes it possible for doctors to directly prescribe cannabis as part of their treatment," the Swiss cabinet said in a statement.

"Growing and processing medical cannabis as well as its sale would then be possible under a system regulated" by Swissmedic, the country's drug regulatory agency.

A formal comment period runs until mid-October.

Just how insurers will handle reimbursement for medical marijuana will be dealt with separately, the government said.

"The biggest obstacle to automatic reimbursement is that the scientific evidence of efficacy is not yet sufficient and the conclusions of existing studies are sometimes contradictory," the government said.

The Federal Health Office will launch an evaluation project to help answer questions about whether the drug is an effective remedy and, if so, for what conditions, it said.

POT PUSH

Switzerland cited increased use of medical marijuana in the treatment of a variety of conditions as driving its initiative. Federal authorities granted around 3,000 exceptions for people seeking to get medical marijuana in 2018.

Elsewhere, medical marijuana is also booming.

Portugal's parliament has approved a bill to legalise marijuana-based medicines, following in the footsteps of Italy, Germany, Canada and parts of the United States. Britain made a similar move in July 2018. are moving, too.

Swiss drugmaker Novartis NOVN.S last year struck a deal with Canadian medical cannabis maker Tilray TLRY.O to support commercialization of some of its products. Switzerland is tinkering with laws that now forbid recreational marijuana, a potential precursor to joining other countries and an increasing number of U.S. states -- Illinois became the latest this week -- in legalizing the drug. plan released in February could let up to 5,000 people smoke marijuana in pilot studies.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.